

Serum glial fibrillary acidic protein as a biomarker of brain injury in premature neonates

Dimitra Metallinou^{1*}, Grigorios Karampas², Georgia Nyktari³, Nicoletta Iacovidou⁴,
Katerina Lykeridou¹, Demetrios Rizos⁵

ABSTRACT

Neonatal brain injury (NBI) is a serious adverse outcome of prematurity. Early detection of high risk premature neonates to develop NBI is not currently feasible. The predictive value of many biomarkers has been tested, but none is used in clinical practice. The purpose of this study was to determine the levels and predictive value of serum glial fibrillary acidic protein (GFAP) in a prospective longitudinal case-control study during the first 3 days of life in premature neonates (<34 weeks of gestation) that later developed either intraventricular hemorrhage or periventricular leukomalacia. Each case (n=29) was matched according to birth weight and gestational age to one neonate with normal head ultrasound scans. No significant differences in GFAP levels were observed between the groups. Nevertheless, neonates with brain injury presented more frequently with GFAP levels above the lowest detection limit (0.056 ng/ml) and this trend was significantly different during all 3 days. Thus, the effectiveness of GFAP as an early biomarker of NBI in premature neonates seems to be limited.

KEYWORDS: Brain injury; glial fibrillary acidic protein; premature neonates; intraventricular hemorrhage; periventricular leukomalacia

INTRODUCTION

Preterm birth (<37 weeks of gestation) is a significant worldwide public health issue with an estimated global rate of 10.6% for the year 2014 with identified data points from 107 countries [1]. Consequences of prematurity are numerous, with the neonatal brain injury (NBI) being one of the most severe ones [2].

The underlying mechanisms of NBI involve an initial insult to the vulnerable fetal brain that is usually either hypoxic-ischemic, hemorrhagic, or infectious in nature. Intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and hypoxic-ischemic encephalopathy (HIE) are the most common subtypes of NBI, which can affect neonates born at any gestational age (GA). However, neonates born <32 weeks of

gestation are more prone to IVH and PVL, while neonates born >35 weeks to HIE [3]. As a consequence, the initial injury activates a cascade of events leading to further brain damage which increases the risk for serious long-term neurodevelopmental impairment, including motor, cognitive, neurologic, and sensory disability [2].

Although noteworthy progress has been made in the management of preterm neonates, the rates of neonatal morbidity and adverse neurodevelopmental outcomes remain high, underlining the need for early, and individualized therapeutic intervention to prevent severe brain injury [3]. Despite the ongoing research, there is currently no available effective prognostic model used in clinical practice, which may provide early detection of neonates at high risk to develop NBI [3,4]. At present, the identification of high risk premature neonates is based mainly on general clinical characteristics such as birth weight <1500 g, GA <28 weeks and perinatal factors associated with brain injury, such as fetal growth restriction or chorioamnionitis [2,4]. In an effort to provide early therapeutic interventions, on the one hand, and prognostic data on survival or density of residual deficits, on the other hand, a number of brain injury biomarkers are under evaluation since clinical but mostly radiological signs remain silent during the first days of life [4,5].

Of the biomarkers associated with brain injury, preliminary research on glial fibrillary acidic protein (GFAP) appears to be promising in the early recognition of NBI in premature neonates [5,6]. GFAP is a brain-specific cytoskeletal intermediate filament protein with a molecular mass between 40 and 53 kDa, which is localized predominantly in astroglial cells

¹Department of Midwifery, University of West Attica, Athens, Greece

²2nd Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, "Aretaieio" University Hospital, Athens, Greece

³Neonatal Intensive Care Unit, "Gaia" Maternity Hospital, Athens, Greece

⁴Neonatal Department, Medical School, National and Kapodistrian University of Athens, "Aretaieio" University Hospital, Athens, Greece

⁵Hormone Laboratory, Medical School, National and Kapodistrian University of Athens, "Aretaieio" University Hospital, Athens, Greece

*Corresponding author: Dr. Dimitra Metallinou, Department of Midwifery, University of West Attica, Ag. Spyridonos Str., Egaleo, Greece. E-mail: metallinou.dimitra@gmail.com

DOI: <https://doi.org/10.17305/bjbms.2021.6205>

Submitted: 18 June 2021/Accepted: 07 July 2021/

Published Online: 19 July 2021

Conflict of interest: The authors declare no conflicts of interest.

Funding: The author(s) received no specific funding for this work.



©The Author(s) (2022). This work is licensed under a Creative Commons Attribution 4.0 International License

and is released as a consequence of brain injury and astrogliosis [6]. Stewart *et al.* [6] demonstrated that levels of circulating GFAP on days 1-4 of life are significantly elevated in preterm neonates that later on developed PVL and that even among neonates with IVH, GFAP could identify which ones were at higher risk for the later development of PVL. Serum GFAP has also been reported by Ennen *et al.* [7]. to be significantly elevated in neonates with GA between 36 and 41 weeks with HIE receiving hypothermia therapy when compared with controls.

Thus, identification of premature neonates who are at risk of developing NBI in the early neonatal period with the use of one or more biomarkers could provide the clinicians with the potential for early intervention. For instance, therapeutic hypothermia in late preterm neonates and brain-focused care, as well as neuroprotective medication in early preterm neonates could probably improve the neurodevelopmental outcomes [8-12]. Yet, there is limited data available regarding the use of GFAP as a biomarker for the early detection of NBI and long-term neurologic outcome, especially in preterm neonates [6]. Furthermore, there is no available study in premature neonates that provides evidence on serum GFAP levels and its predictive value comparing GFAP with the levels and predictive value of other biomarkers, such as S100B, in the same study population and this makes our study of great interest [13].

The purpose of this study was to determine whether serum GFAP levels measured within the first 3 days of life differ between premature neonates (<34 weeks) (a) with and without NBI, (b) with IVH and those with PVL, and (c) with different grades of NBI as well as (d) to evaluate the predictive value of serum GFAP during the first 3 days of life to early identify high-risk premature neonates that will either develop NBI or will be complicated with a severe adverse neonatal outcome such as death or seizures/hypertonia.

Definitions of NBI

IVH

IVH typically initiates in the periventricular germinal matrix, which is particularly vulnerable to hemorrhage in premature neonates mostly in the first 48 h of life [14]. The classic grading system of IVH was initially described by Papile *et al.* [15]. Findings are graded on a scale from I to IV [16] and it is estimated that it affects 15-20% of the neonates born <32 weeks [2,15-17].

PVL

PVL is defined as injury to the deep cerebral white matter that can be seen in two characteristic patterns: (a) Focal

necrosis with loss of all cellular elements in periventricular white matter and (b) diffuse lesion in cerebral white matter [18]. It is the most common type of brain injury in premature neonates, often associated with or considered as a direct consequence of IVH, but also seen in the absence of IVH. Developmental outcomes for neonates with PVL are related to the grade and location of parenchymal involvement [19]. According to Romero-Guzman *et al.* [18], prevalence is estimated under 28 weeks at 39.6%, under 32 weeks at 27.4%, and under 37 weeks at 7.3% and it is classified on a scale from I to IV [20].

MATERIALS AND METHODS

This is an Institutional Review Board (IRB) approved prospective longitudinal case-control study of live born premature (<34 weeks) neonates, born at a single tertiary hospital, who were admitted to the Neonatal Intensive Care Unit (NICU) between November 2016 and March 2018 ("Aretaieio" University Hospital - IRB R.No: B-216/13-10-2016/APPROVAL NUMBER-ID: KM140657). The study is part of a wider research protocol on the levels and predictive value of brain injury biomarkers in premature neonates with and without NBI and was carried out according to "ICMJE Recommendations for the Protection of Research Participants" [13]. All procedures were in accordance with the Declaration of Helsinki.

Inclusion criteria were (a) prematurity (<34 weeks) and (b) NBI in the form of either PVL or IVH for the case group. Neonates with major congenital, genetic, or chromosomal abnormalities as well as other types of NBI, such as HIE, were excluded from the study. Only neonates whose parents gave their written informed consent were included in the study.

All neonates were admitted to NICU right after delivery. According to the NICU's protocol, on admission routine laboratory investigation included complete blood count (CBC), blood culture, and C-reactive protein (CRP). CBC and CRP should be additionally assessed in all premature neonates on the 2nd and 3rd day of life. Any unused quantity of serum was then used for the measurement of GFAP. Blood was collected from peripheral or umbilical vessels and the residual serum was aliquoted and stored at -35°C until assayed.

NBI was classified at discharge taking into account head ultrasound scans (HUS) and the neonates were allocated in the case or control group. HUS followed the European Standards of Care for Newborn Health (ESCNH) [21] and were all performed in the NICU and evaluated by the Consultant Paediatric Radiologist of the Hospital. HUS through the cranial fontanelles is considered as the gold standard for the diagnosis of NBI, allowing rapid bedside

evaluation of the neonatal brain [22-24]. Until now, there is no universally accepted protocol for HUS screening in preterm neonates [21,24]. According to the protocol of ESCNH [21], a HUS should be performed in preterm neonates on days 1, 3, 7, 14, 21, and 28 at 6 weeks and at term equivalent age (TEA) if GA is >28 weeks. If GA is <28 weeks, a HUS should be performed on days 1, 3, 7, 14, 21, and 28 then for every 2 weeks until the 34th week GA and at TEA. Finally, a HUS should be intensified in case of abnormalities or after episodes of clinical deterioration (e.g., unexplained anemia, neurological symptoms, surgery, HIE, central nervous system infection, and metabolic disease).

Medical records were reviewed by the study personnel to identify relevant maternal and neonatal data regarding clinical and laboratory perinatal factors that could be of interest to either influence or predict NBI. Before any statistical analysis accuracy of data collection was double checked by the study personnel. Coding of all participants (mothers and neonates) was automatically created by the database used, to preserve anonymization/deidentification.

High-risk pregnancy was defined according to international standards and guidelines including preeclampsia [25], oligohydramnios [26], hypothyroidism [27], gestational diabetes mellitus [28], chorioamnionitis [29], fetal growth restriction [30], and pathological Doppler [31].

Determination of GFAP concentrations was performed with one of the most sensitive commercially available kits (GFAP - MBS2701011, GFAP, ELISA) from MyBioSource, USA. According to the kit's inserts, the lowest detection limit was 0.056 ng/ml and the precision, as estimated by the total CV (%), was <10%. Values <0.056 ng/mL were reported as zero.

Statistical Analysis

Statistical analysis was crosschecked and performed by the research team with the use of the commercially available software package: IBM SPSS statistics version 23 (IBM Corporation, Somers, NY 10589, USA). As there were no available studies on the levels of serum GFAP in the general population of premature neonates complicated with the development of NBI, sample size calculation for this wider research protocol was based on the levels of S100B, which is considered as the "gold standard" of NBI biomarkers [13]. Clinical characteristics and laboratory findings of women and neonates included in the study were compared in an effort to assure the success of the matching and to specify dissimilarities between the two groups. Pearson's Chi-square test (χ^2) was performed for comparisons of qualitative data. One-Sample Kolmogorov–Smirnov test was done to control the normality of the distribution of GFAP and the rest of the quantitative parameters. Based on this analysis,

either parametric t-test or Mann–Whitney U-test was used to compare GFAP concentration and the other quantitative parameters between the groups. Kruskal–Wallis test was applied to compare levels of GFAP within groups. Control and neonates with either PVL or IVH were included in a subgroup analysis, so as to investigate if GFAP levels varied in different types of NBI. Further subgroup analysis was made to compare GFAP levels in the five deceased neonates of the case group with the levels of control neonates and the rest of the cases, on purpose to identify if GFAP's levels are altered in case of imminent death during the early neonatal period. Finally, the value of serum GFAP to predict NBI in the first 3 days of life was examined through multivariate logistic regression analysis setting as dependent variable either (a) the development or not of NBI during hospitalization in NICU or (b) the presence or not of Grade II-IV IVH complicated by seizures/hypertonia or death, and as independent variables the levels of serum GFAP and S100B [13] in the same study population during the first 3 days of life. A probability level of less or equal to 0.05 was considered significant.

RESULTS

In this wide research protocol ninety-six (n=96) neonates fulfilled the inclusion criteria and were finally included in the study [13]. Sixty-five (n=65) of these neonates did not develop NBI while the rest thirty-one (n=31) were complicated with a type of NBI. From the latter, seventeen neonates developed PVL (n=17), twelve IVH (n=12), and two HIE which were excluded from the study. Consequently, the case group consisted of twenty-nine (29) neonates. Sixteen (n=16) neonates from the PVL group were diagnosed with Grade I unilateral or bilateral PVL and one with Grade II unilateral PVL. From the IVH group (n=12), four (n=4) neonates were diagnosed with Grade I unilateral or bilateral IVH and eight (n=8) with Grade II-IV unilateral or bilateral IVH. Six (n=6) neonates of the IVH group had seizures during hospitalization and three (n=3) finally died. The rest three (n=3), apart from seizures, also developed hypertonia. Totally, five (n=5) neonates died, all of which were diagnosed with IVH.

From the sixty-five neonates with normal HUS, twenty-nine were selected to constitute the control group. Matching between cases (n=29) and controls (n=29) was conducted manually in a 1:1 fashion, taking into account closeness of GA (within 1 week) and birth weight. The mean and standard deviation (SD) GA for control neonates and cases were 29.8 ± 2.5 weeks and 29.6 ± 3.0 weeks while birth weight at admission was 1302 ± 429 gr and 1225 ± 475 gr, respectively (Tables 1 and 2).

TABLE 1. Maternal demographic and clinical characteristics of control and cases neonates

Variable	Control	Cases	p-value
n	29	29	
Maternal age (years)	38.4±5.8	37.9±5.7	0.764
Gestational age (weeks)	29.8±2.5	29.6±3.0	0.817
Parity, n (%)			
Nullipara	22 (76)	22 (76)	>0.99
Multipara	7 (24)	7 (24)	
Maternal/Neonatal Ethnicity, n (%)			
Greek	29 (100%)	29 (100%)	>0.99
Race, n (%)			
Caucasian	29 (100%)	29 (100%)	>0.99
Conception, n (%)			
Normal	9 (31)	11 (38)	0.581
IVF	20 (69)	18 (62)	
Gestation, n (%)			
Single	13 (45)	8 (28)	0.172
Multiple	16 (55)	21 (72)	
Caesarean delivery, n (%)	28 (97)	25 (86%)	0.160
Preterm premature rupture of membranes, n (%)	9 (31)	9 (31)	>0.99
Preeclampsia, n (%)	4 (14)	1 (3.5)	0.160
Oligohydramnios, n (%)	2 (7)	2 (7)	>0.99
Hypothyroidism, n (%)	15 (52)	11 (38)	0.291
Insulin dependent gestational diabetes mellitus, n (%)	4 (14)	2 (7)	0.389
Pathological Doppler, n (%)	3 (10)	6 (20)	0.277
Antenatal steroid administration, n (%)	25 (86)	23 (79)	0.487
Neonates with PVL		16/17	
Neonates with IVH		7/12	0.019
Antenatal magnesium sulfate administration, n (%)	11 (38)	15 (52)	0.291
Abruptio placenta, n (%)	1 (3.5)	1 (3.5)	>0.99
Clinical chorioamnionitis, n (%)	7 (24)	3 (10)	0.164

IVF: *In vitro* fertilization; PVL: Periventricular leukomalacia; IVH: Intraventricular hemorrhage

Comparison between cases and control neonates for maternal demographic and clinical characteristics identified no differences except for the antenatal use of corticosteroids between women whose neonates developed IVH and those that developed PVL (Table 1).

Neonatal demographic – clinical characteristics and laboratory findings between the case and control group are presented in Table 2. Neonates in the case group had significantly lower admission pH and white blood cells count when compared to control neonates while admission base deficit and concentration of lactic acid were higher in neonates in the case group. Moreover, no difference was observed on therapeutic interventions in neonates between the two groups (Table 3). Finally, regarding neonatal outcomes (Table 4), necrotizing enterocolitis was more frequent in control neonates while seizures and death were more frequent in the case group.

Serum GFAP levels were available for comparison at 85/87 (97.7%) of the desired time points for both case and control group. Missing data were due to insufficient serum after routine investigation had been performed.

TABLE 2. Neonatal demographic - clinical characteristics and laboratory findings of control and cases neonates

Variable	Control	Cases	p-value
n	29	29	
Sex, n (%)			
Male	13 (45)	12 (41)	0.791
Female	16 (55)	17 (59)	
Apgar score, median (IQR)			
1 st min	8 (2)	8 (3)	0.089
5 th min	9 (1)	9 (1)	0.665
Apgar score <7, n (%)			
1 st min	5 (17)	9 (31)	0.220
5 th min	0 (0)	1 (3.5)	0.274
Admission birth weight, gr	1302±429	1225±475	0.517
Discharge weight, gr	2837±576	2613±385	0.134
Admission head circumference, cm	27.5±2.5	27.0±3.2	0.533
Discharge head circumference, cm	33.5±1.4	33.5±1.1	0.915
Admission, arterial blood			
pH	7.37±0.01	7.29±0.16	0.033
Base deficit, mmol/L	4.29±1.92	7.22±6.59	0.037
pCO ₂ , mmHg	38±10	40±10	0.371
HCO ₃ , mmol/L	20±2	19±5	0.087
Lactic acid, mmol/L	3.1±1.2	4.8±4.3	0.05
Hb, g/dl	16.5±3.0	16.9±2.0	0.438
WBC count, K/μL	11456±9550	9153±5562	0.05
CRP, mg/L	1.0±0.2	1.3±1.5	0.998
Positive CRP at admission, n (%)	14 (48)	12 (41)	0.597
CRP 2 nd day, mg/L	6.1±8.7	4.9±8.7	0.294
CRP 3 rd day, mg/L	7.6±11.1	6.0±7.5	0.809

IQR: Interquartile range; WBC: White blood cells; CRP: C-reactive protein

TABLE 3. Therapeutic interventions of control and cases neonates

Variable	Control	Cases	p-value
n	29	29	
Surfactant, n (%)	21 (72)	22 (76)	0.764
Inotropes, n (%)	14 (48)	20 (69)	0.145
Caffeine, n (%)	26 (90)	25 (86)	0.687
Cardiopulmonary resuscitation, n (%)	3 (10)	6 (20)	0.277
Patent ductus arteriosus treatment, n (%)	8 (28)	8 (28)	>0.99
Paracetamol	2	0	
Ibuprofen	5	7	
Surgery	1	1	
High frequency ventilation, n (%)	4 (14)	7 (24)	0.315
Transfusion, n (%)	3 (10)	7 (24)	0.164

NICU: Neonatal intensive care unit

Mean ± SD and Median – Interquartile Range of GFAP levels are presented in Table 5. No difference was observed within groups during the first 3 days of life. Moreover, GFAP levels did not differ significantly between control neonates with and without necrotizing enterocolitis. Although mean GFAP concentration (ng/ml) was higher in the case group in all days, this difference was not significant (Table 5, Figure 1).

It is worth mentioning though, that neonates in the case group presented more frequently GFAP levels above the

TABLE 4. Neonatal outcomes of control and cases neonates

Outcome	Control	Cases	p-value
n	29	29	
Seizures, n (%)	0 (0)	6 (20)	0.01
Hypertonia, n (%)	0 (0)	2 (7)	0.15
Death, n (%)	0 (0)	5 (17)	0.019
Neonates with PVL		0/17	
Neonates with IVH		5/12	0.015
Positive blood culture, n (%)	1 (3.5)	2 (7)	0.553
Positive cerebrospinal fluid culture, n (%)	0 (0)	1 (3.5)	0.274
Clinical neonatal sepsis, n (%)	1 (3.5)	2 (7)	0.553
Respiratory distress syndrome, n (%)	21 (72)	23 (79)	0.539
Chronic lung disease, n (%)	6/27 (22)	5/21 (24)	0.897
Necrotizing enterocolitis, n (%)	6 (20)	1 (3.5)	0.044
Otoacoustic Emissions Test negative, n (%)	7/23 (30)	9/21 (43)	0.392
Automated auditory brainstem response test negative, n (%)	4/11 (36)	4/10 (40)	0.864
Length of stay in NICU, days	63±48	45±30	0.089

PVL: Periventricular leukomalacia; IVH: Intraventricular hemorrhage

TABLE 5. Mean ± Standard Deviation (SD), Median (Interquartile Range, IQR) and frequency of concentrations of Glial Fibrillary Acidic Protein (ng/ml) below the lowest detection limit in neonates with and without brain injury during the first 3 days of life


n	Control	Cases
	29	29
1 st Day		
Mean ± SD	0.183±0.194	0.241±0.247
Median (IQR)	0.165 (0.29)	0.185 (0.14)
n (%) < Detection limit	10 (35)	2 (7)*
2 nd Day		
Mean ± SD	0.202±0.159	0.232±0.232
Median (IQR)	0.185 (0.25)	0.160 (0.17)
n (%) < Detection limit	6 (20)	1 (3.5)#
3 rd Day		
Mean ± SD	0.202±0.156	0.239±0.223
Median (IQR)	0.190 (0.2)	0.165 (0.17)
n (%) < Detection limit	6 (20)	1 (3.5)#

*p=0.006; #p=0.044 compared to controls

kit's lowest detection limit (0.056 ng/ml) and these percentages were significantly different during the first 3 days of life ($p < 0.05$, Pearson's Chi-square test) (Table 5). Moreover, as shown in Figure 1, neonates in the case group presented more frequently very high levels of GFAP (outliers) but these measurements were not necessarily associated with neonates that died.

Further subgroup analysis among control neonates and neonates with either IVH or PVL revealed no significant difference on the levels of GFAP (results not shown). Notably, when the five neonates that died in the case group were compared to either control or the rest of the neonates with NBI, no significant difference was observed during the first 3 days of life (results not shown).

Interestingly, additional subgroup analysis between neonates with PVL and IVH showed that neonates whose

**FIGURE 1.** Concentration of serum Glial Fibrillary Acidic Protein (ng/mL) in neonates with and without brain injury during the first 3 days of life. Box plots (horizontal line: median; box: 25-75% percentiles; whiskers: min-max; asterisk: outliers).

mothers received antenatal corticosteroids (Table 1) developed more frequently PVL instead of IVH and had significantly lower probability of neonatal death during hospitalization (Table 4).

Finally, the multivariable logistic regression analysis including as independent variables serum GFAP and S100B levels during the first 3 days of life confirmed that the predictive value of serum GFAP, regarding either the development of NBI or a severe adverse neonatal outcome such as II-IV grade IVH complicated by seizures/hypertonia or death, is limited, as it did not reach statistical significance (results not shown).

DISCUSSION

At present, there is no model or biomarker that can detect premature neonates at high risk for developing NBI [32-34]. Head ultrasound imaging is considered as the gold standard for the diagnosis but not the prediction of NBI in neonates, especially premature ones that will develop either PVL or IVH [22-24]. Moreover, MRI has been shown to identify moderate-to-severe cerebral white matter injury that can predict adverse neurodevelopmental outcome but again its predictive value regarding NBI in the first days of life is limited [21,35,36]. Early detection of premature neonates that will later on in life develop NBI is crucial, as early therapeutic interventions might moderate neurodevelopmental defects. Numerous biomarkers have been investigated regarding their

prognostic value for NBI, but data on the efficacy of GFAP in preterm neonates remain limited.

In the present study, we demonstrate that levels of serum GFAP on days 1-3 of life are elevated in preterm neonates which will later develop NBI. While elevated the difference was not statistically significant. Our findings differ to these by Stewart *et al.* [6] who detected a significant difference between normal and neonates with NBI. However, the case group in Stewart's study consisted of either very low birth weight (VLBW) (<1500 g) or LBW neonates (1500-2500 g) "with suspected neurologic morbidity at birth, which included prolonged hypotonia or seizures," while the case group in our study was more representative of the general population of premature neonates as no weight limit or neurologic morbidity was set as inclusion criteria. Furthermore, many neonates in Stewart's study developed both PVL and IVH and as mentioned in the same study "GFAP was significantly increased in neonates with both IVH and PVL on days 2-4 of life" when compared to neonates with IVH only. Consequently, when combined, PVL and IVH can elevate cumulatively the levels of GFAP contributing to higher levels in the case group. Contrarily, in our study, the case group consisted of neonates with either PVL or IVH, but not both, representing a well separated study population in terms of subsequent pathology. Nevertheless, as in the study by Stewart *et al.*, we identified a clear trend as GFAP was detected more frequently below the lowest detection limit (0.056 ng/ml) in the control group compared to neonates with NBI.

Our findings are also consistent with the observation that neither neonates that died (n=5) nor those with II-IV grade IVH showed significantly higher GFAP concentrations when compared to neonates of either the control or case group during the first 3 days of life (results not shown). Although the levels of GFAP were more elevated in these neonates when compared to controls, it seems that GFAP is either of limited value in the prognosis of NBI in the general population of premature neonates or not as powerful as other biomarkers, such as S100B [37,38]. The latter is considered as one of the most effective biomarkers to predict severe types of NBI in premature neonates according to a number of previous studies, including ours [13]. More specifically, in our previous study for a cutoff value of 10.51 ng/ml, serum S100B on the 1st day of life performed an excellent sensitivity of 100% and specificity of 93.9% to predict severe adverse neonatal outcome such as death or IVH of II-V grade complicated with seizures and/or hypertonia.

The fact that we have investigated both GFAP and S100B in the same study population is an important strength of our study as no previous study provides evidence on the

prognostic value of GFAP when directly compared to the most well studied biomarker of NBI in premature neonates. Another strength of our study is the prospective longitudinal methodology, which allows the repetitive evaluation of GFAP levels. Following that methodology, the absence of significant difference between control and case neonates was confirmed during the first 3 days of life which is the most important period for the early detection of premature neonates at risk to develop NBI.

While not a primary aim of this study, we observed that antenatal corticosteroids, specifically betamethasone, have a neuroprotective effect. In both our study and the study by Stewart *et al.* [6] neonates whose mothers received antenatal steroids were less likely to develop IVH and had significantly lower rates of mortality.

Finally, our study has some limitations as well. A main limitation is the low number of neonates in both groups which could explain the fact that differences on serum GFAP between the two studied groups did not reach statistical significance. Nonetheless, in our previous study with the same study population, differences on serum S100B levels were significant already from the 1st day of life, indicating that differences on GFAP levels are limited [13]. Moreover, even though we used one of the most sensitive commercial kits for serum GFAP, many neonates in the control group presented GFAP levels below the lowest detection limit, which indicates that future studies should consider using a more sensitive method to measure serum GFAP levels, and consequently determine its predictive value regarding NBI in premature neonates more accurately.

CONCLUSION

We report that serum GFAP levels in premature neonates (<34 weeks) that develop NBI do not differ significantly to the levels of neonates without NBI during the first 3 days of life. Consequently, its effectiveness as an early predictive biomarker of NBI in the general population of premature neonates is probably limited. However, premature neonates without NBI had more often GFAP levels below the lowest detection limit. Therefore, a more sensitive detection method for serum GFAP in the future might highlight its predictive role in the early identification of NBI in the general population of premature neonates.

ACKNOWLEDGMENTS

The authors would like to thank the laboratory staff members Kapetanaki Antigoni, Zisi Georgiα and Vrachnou Nota-Maria for data documentation and skillful technical assistance.

REFERENCES

- [1] Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global regional and national estimates of levels of preterm birth in 2014: A systematic review and modelling analysis. *Lancet Glob Health* 2019;7(1):e37-46. [https://doi.org/10.1016/s2214-109x\(18\)30451-0](https://doi.org/10.1016/s2214-109x(18)30451-0).
- [2] Novak CM, Ozen M, Burd I. Perinatal brain injury: Mechanisms, prevention, and outcomes. *Clin Perinatol* 2018;45(2):357-75.
- [3] Larroque B, Ancel PY, Marret S, Marchand L, André M, Arnaud C, et al. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): A longitudinal cohort study. *Lancet* 2008;371:813-20. [https://doi.org/10.1016/s0140-6736\(08\)60380-3](https://doi.org/10.1016/s0140-6736(08)60380-3).
- [4] Bersani I, Pluchinotta F, Dotta A, Savarese I, Campi F, Auriti C, et al. Early predictors of perinatal brain damage: The role of neurobiomarkers. *Clin Chem Lab Med* 2020;58(4):471-86. <https://doi.org/10.1515/cclm-2019-0725>.
- [5] Douglas-Escobar M, Weiss MD. Biomarkers of brain injury in the premature infant. *Front Neurol* 2013;185:1-7.
- [6] Stewart A, Tekes A, Huisman T, Jennings JM, Allen MC, Northington FJ, et al. Glial fibrillary acidic protein as a biomarker for periventricular white matter injury. *Am J Obstet Gynecol* 2013;209(1):27.e1-7. <https://doi.org/10.1016/j.ajog.2013.02.049>.
- [7] Ennen CS, Huisman TA, Savage WJ, Northington FJ, Jennings JM, Everett AD, et al. Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole body cooling. *Am J Obstet Gynecol*. 2011;205(3):251.e1-7. <https://doi.org/10.1016/j.ajog.2011.06.025>.
- [8] van Tilborg E, Heijnen CJ, Benders MJ, van Bel F, Fleiss B, Gressens P, et al. Impaired oligodendrocyte maturation in preterm infants: Potential therapeutic targets. *Prog Neurobiol* 2016;136:28-49. <https://doi.org/10.1016/j.pneurobio.2015.11.002>.
- [9] Parikh P, Juul SE. Neuroprotective strategies in neonatal brain injury. *J Pediatr* 2018;192:22-32.
- [10] Juul SE, Ferriero DM. Pharmacologic neuroprotective strategies in neonatal brain injury. *Clin Perinatol* 2014;41:119-31. <https://doi.org/10.1016/j.clp.2013.09.004>.
- [11] Bonifacio SL, Van Meurs K. Neonatal neurocritical care: Providing brain-focused care for all at risk neonates. *Semin Pediatr Neurol* 2019;32:100774. <https://doi.org/10.1016/j.spen.2019.08.010>.
- [12] Altimier L, Phillips R. Neuroprotective care of extremely preterm infants in the first 72 hours after birth. *Crit Care Nurs Clin North Am* 2018;30(4):563-83. <https://doi.org/10.1016/j.cnc.2018.07.010>.
- [13] Metallinou D, Karampas G, Nyktari G, Iacovidou N, Lykeridou K, Rizos D. S100B as a biomarker of brain injury in premature neonates. A prospective case-control longitudinal study. *Clin Chim Acta* 2020;510:781-6. <https://doi.org/10.1016/j.cca.2020.09.013>.
- [14] Ballabh P. Intraventricular hemorrhage in premature infants: Mechanism of disease. *Pediatr Res* 2010;67(1):1-8. <https://doi.org/10.1203/pdr.0b013e3181c1b176>.
- [15] Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm. *J Pediatr* 1978;92(4):529-34. [https://doi.org/10.1016/s0022-3476\(78\)80282-0](https://doi.org/10.1016/s0022-3476(78)80282-0).
- [16] Volpe JJ. *Neurology of the Newborn*. 5th ed. Philadelphia, PA: Saunders, Elsevier; 2008.
- [17] Szepecht D, Szymankiewicz M, Nowak I, Gadzinowski J. Intraventricular hemorrhage in neonates born before 32 weeks of gestation-retrospective analysis of risk factors. *Childs Nerv Syst* 2016;32(8):1399-404. <https://doi.org/10.1007/s00381-016-3127-x>.
- [18] Romero-Guzman GJ, Lopez-Munoz F. Prevalence and risk factors for periventricular leukomalacia in preterm infants. A systematic review. *Rev Neurol* 2017;65(2):57-62.
- [19] Chen HJ, Wei KL, Zhou CL, Yao YJ, Yang YJ, Fan XF, et al. Incidence of brain injuries in premature infants with gestational age ≤ 34 weeks in ten urban hospitals in China. *World J Pediatr* 2013;9(1):17-24. <https://doi.org/10.1007/s12519-012-0395-8>.
- [20] Ahya KP, Suryawanshi P. Neonatal periventricular leukomalacia: Current perspectives. *Res Rep Neonatol* 2018;8:1-8. <https://doi.org/10.2147/rn.s125575>.
- [21] Dudink J, Hellström-Westas L, Zimmermann L, Buonocore G, Gressens P, Pellicer A. Neurological Monitoring in the High-risk Infant: Ultrasound and MRI Scanning. 2018. European Foundation for the Care for Newborn Health. Available from: <https://www.newborn-healthstandards.org/ultrasound-and-mri>. [Last accessed on 2021 May 05].
- [22] Smyser CD, Wheelock MD, Limbrick DD Jr, Neil JJ. Neonatal brain injury and aberrant connectivity. *Neuroimage* 2019;185:609-23. <https://doi.org/10.1016/j.neuroimage.2018.07.057>.
- [23] Hinojosa-Rodriguez M, Harmony T, Carrillo-Prado C, Van Horn JD, Irimia A, Torgerson C, et al. Clinical neuroimaging in the preterm infant: Diagnosis and prognosis. *Neuroimage Clin* 2017;16:355-68. <https://doi.org/10.1016/j.nicl.2017.08.015>.
- [24] Ment LR, Bada HS, Barnes P, Grant PE, Hirtz D, Papile LA, et al. Practice parameter: Neuroimaging of the neonate: Report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society. *Neurology* 2002;58(12):1726-38. <https://doi.org/10.1212/wnl.58.12.1726>.
- [25] Portelli M, Baron B. Clinical presentation of preeclampsia and the diagnostic value of proteins and their methylation products as biomarkers in pregnant women with preeclampsia and their newborns. *J Pregnancy* 2018;2018:2632637. <https://doi.org/10.1155/2018/2632637>.
- [26] Mushtaq E, Parveen S, Shaheen F, Jan S, Abdullah A, Lone YA. Perinatal outcome in patients with isolated oligohydramnios at term: A prospective study. *J Preg Child Health* 2017;4:332. <https://doi.org/10.4172/2376-127x.1000332>.
- [27] McNeil AR, Stanford PE. Reporting thyroid function tests in pregnancy. *Clin Biochem Rev* 2015;36(4):109-26.
- [28] Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al, International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33(3):676-682. <https://doi.org/10.2337/dco9-1848>.
- [29] Roberto R, Chaemsaitong P, Korzeniewski SJ, Kusanovic JP, Docheva N, Martinez-Varea A, et al. Clinical chorioamnionitis at term III: How well do clinical criteria perform in the identification of proven intra-amniotic infection? *J Perinat Med* 2016;44(1):23-32. <https://doi.org/10.1515/jpm-2015-0044>.
- [30] Buck Louis GM, Grewal J, Albert PS, Sciscione A, Wing DA, Grobman WA, et al. Racial/ethnic standards for fetal growth: The NICHD fetal growth studies. *Am J Obstet Gynecol* 2015;213(4):449.e1-41. <https://doi.org/10.1016/j.ajog.2015.08.032>.
- [31] Ciobanu A, Wright A, Syngelaki A, Wright D, Akolekar R, Nicolaides KH. Fetal medicine foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. *Ultrasound Obstet Gynecol* 2019;53(4):465-72. <https://doi.org/10.1002/uog.20157>.
- [32] Chalak LF. Inflammatory biomarkers of birth asphyxia. *Clin Perinatol* 2016;43(3):501-10.
- [33] Florio P, Abella R, Marinoni E, Di Iorio R, Li Volti G, Galvano F, et al. Biochemical markers of perinatal brain damage. *Front Biosci (Schol Ed)* 2010;2:47-72.
- [34] Mir IN, Chalak LF. Serum biomarkers to evaluate the integrity of the neurovascular unit. *Early Hum Dev* 2014;90(10):707-11. <https://doi.org/10.1016/j.earlhumdev.2014.06.010>.
- [35] Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal

- distress. A clinical and electroencephalographic study. *Arch Neurol* 1976;33(10):696-705.
<https://doi.org/10.1001/archneur.1976.00500100030012>.
- [36] Sewell EK, Andescavage NN. Neuroimaging for neurodevelopmental prognostication in high-risk neonates. *Clin Perinatol* 2018;45(3):421-37.
<https://doi.org/10.1016/j.clp.2018.05.004>.
- [37] Huang RZ, Zhang YJ, Zhang JF, Su YM, Peng LQ, Ya N. Relation between prognosis and changes of MBP and S100B in premature infants with periventricular leukomalacia. *Genet Mol Res* 2015;14(2):4338-43.
<https://doi.org/10.4238/2015.april.30.6>.
- [38] Chiang LM, Chen WY, Yang YC, Jeng MJ. Elevation of serum S100 protein concentration as a marker of ischemic brain damage in extremely preterm infants. *J Chin Med Assoc* 2015;78(10):610-6.
<https://doi.org/10.1016/j.jcma.2015.06.009>.
-

Related articles published in BJBMS

1. [Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection](#)
Abulizi Abudula et al., BJBMS, 2019
2. [The importance of determining procalcitonin and C reactive protein in different stages of sepsis](#)
Zana Baruti-Gafurri et al., BJBMS, 2010